Product
Help
Pricing
About
Jobs
Log in
Get started
Work
Add to collection
Investigational drugs in development to prevent neuromyelitis optica relapses
HTML
Details
Locations
Year:
2018
Type:
review
Source:
Expert Opinion on Investigational Drugs
DOI:
10.1080/13543784.2018.1443077
Authors:
Friedemann Paul,
Olwen Murphy,
Santiago Pardo,
Michael Levy
Institutions:
Max Delbrück Center,
Humboldt-Universität zu Berlin,
Charité – Universitätsmedizin Berlin,
Johns Hopkins University
Language:
English
Topic:
Multiple Sclerosis Research Studies
Subfield:
Clinical Neurology
Field:
Medicine
Domain:
Health Sciences
Keywords:
neuromyelitis optica spectrum disorder,
relapse prevention,
eculizumab,
complement inhibition,
IL-6 receptor inhibition,
B-cell depletion,
neuropathic pain,
clinical trial design
show all 8
SDG:
Good health and well-being
Open Access status:
closed
Funders:
Deutsche Forschungsgemeinschaft,
Bundesministerium für Bildung und Forschung
Awards:
G3584538239,
Kompetenznetz Multiple Sklerose: Antikörpersignaturen als Biomarker für Diagnose, Prognose und Therapieansprechen in pathologisch definierten Subtypen der Multiplen Sklerose sowie der Neuromyelitis optica (TP Pattern MS/NMO)
OpenAlex ID:
W2790969836
FWCI:
1.385
Cites:
92
Cited by:
46
Related to:
10